Prostate Cancer

In this episode, Adam Weiner, MD, and Michael Leapman, MD, discuss the current state of active surveillance for intermediate-risk prostate cancer.

The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure.

Pedro C. Barata, MD, MSc, FACP, outlines ARANOTE findings stratified by age subgroups.

Louise K. Kostos, MBBS, FRACP, PhD candidate, outlines initial findings from the phase 1/2 AlphaBet trial.

Initial data on pasritamig showed that the agent was well-tolerated and had encouraging preliminary anti-tumor activity in patients with mCRPC.

The mean baseline FACT-G total score for the niraparib group was 79.7 (standard deviation [SD], 14.9) and was 79.3 (SD, 15.2) for the placebo group.

Jeremie Calais, MD, PhD, shares key findings from the phase 2 LUNAR trial, assessing the safety and efficacy of adding 177Lu-PSMA therapy before SBRT in omHSPC.

“Overall, the combination of saruparib plus an ARPI was well tolerated," Arun Azad, PhD, MBBS.

"The primary end point was met, showing a statistically significant rPFS benefit with the combination of capivasertib and abiraterone," said Karim Fizazi, MD, PhD.

Stephen J. Freedland, MD, reported that with combination enzalutamide/leuprolide, the risk of death was 40.3% lower vs leuprolide alone.

Stephen J. Freedland, MD, shares 'unprecedented' overall survival data from the phase 3 EMBARK trial.

The grade 3-5 AE rate was 78.9% (95% CI, 70.8-85.6) in the 75 mg/m2 arm vs 61.2% (95% CI, 51.9-69.9) in the 50 mg/m2 arm (P =.0024).

The new CPT code will be effective starting on July 1, 2026.

The phase 2 Co-PSMA trial has met its primary end point.

Michael J. Morris, MD, discusses the mechanism of action for AB001, PSMA-targeted radioligand therapy for patients with mCRPC.

The trial will assess the effect of adding docetaxel to SOC hormone therapy plus apalutamide in mCSPC.

Discover how language and trauma-informed care reshape patient experiences in sexual medicine and improve outcomes.

The phase 1 trial is assessing VIR-5500 as both a monotherapy and in combination with ARPIs in prostate cancer.

SBRT demonstrated favorable 4-year biochemical recurrence-free survival with a manageable safety profile.

The study is assessing the safety and tolerability of the CaverSTIM device for ED after surgical removal of the prostate.

The PROSTOX ultra test can predict which patients with localized prostate cancer are at a higher risk of GU toxicity from SBRT.

Veda N. Giri, MD, outlines alternative care delivery models that could help improve access to genetic testing for prostate cancer.

Data showed that adding niraparib to AAP significantly improved radiographic progression-free survival in this patient population.

CAN-2409 plus valacyclovir significantly improved disease-free survival compared with placebo plus valacyclovir.